The USPSTF is an independent panel of experts in prevention and primary care that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventative services. The USPSTF is commissioned by the Agency for Healthcare Research and Quality, which is a program of the Department of Health and Human Services.
The USPSTF Recommendation Statement is not consistent with recommendations from other entities. Expert panels convened by the Department of Health and Human Services, the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Veteran's Administration (VA) and the American Association for the Study of Liver Diseases concur; they recommend testing for people who are at risk for hepatitis C:
What is the impact of this recommendation? According to Andi Thomas, founder and Executive Director of Hep-C Alert and President of the National Hepatitis C Advocacy Council, "We'll see it over time, as the USPSTF Recommendation Statement gets incorporated into evidence-based prevention programming, CME activities and the education of new doctors."
In fact, a CME program incorporating these guidelines has already appeared on Medscape. The inconsistency between the USPSTF Recommendation Statement and the HCV screening recommendations from NIH and CDC are listed only in the last three bullet points (of 21). One of two "Pearls for Practice" summarizing this CME states:
"There is insufficient evidence that newer treatments improve long-term health outcomes and disease progression. The USPSTF also cannot determine the benefits vs. harms of screening adults at high risk at this time."
The failure to recommend HCV testing for high-risk individuals has disturbing implications for the fundamental right to medical care. People at risk for a chronic, potentially life-threatening illness are entitled to testing, even in the absence of data on the long-term outcomes of those treated for the condition. The Recommendation Statement may have a deleterious effect on public health; without testing, key prevention opportunities are forfeited as people with hepatitis C go undiagnosed.
Under-funded entitlement programs may use the USPSTF Recommendation Statement as a rationale for denying reimbursement for HCV testing. This will have the greatest impact on those at highest risk for HCV infection: current and former injection drug users (up to 90% may be infected), prisoners (estimated prevalence of 30-40%), and African American men from 40 to 49 years of age, among whom HCV is far more prevalent than the general population (9.8% vs. 1.8%).
According to Thomas, "this is a symptom of a much bigger problem: the lack of funded infrastructure for hepatitis C services in the U.S." Thomas and her colleagues at the National Hepatitis C Advocacy Council have written legislation to create the needed infrastructure (see www.hepcnetwork.org/legislation.htm for more information about the Hepatitis C Epidemic Prevention and Control Act).
The CDC just announced that they are trimming two million dollars from their already meager Viral Hepatitis budget; now less funding will be going towards integration of HCV education and testing into HIV programming (among other demonstration projects). We need these programs; what benefits people who are at risk for, or infected with, hepatitis C will benefit coinfected people as well. Hepatitis C is an opportunistic infection of HIV disease. End-stage liver disease resulting from hepatitis C coinfection has become a leading cause of death among people with HIV.
Back to the TAGline June 2004 contents page.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Long-Acting HIV Treatment: 5 Myths and Realities|
|Two-Drug HIV Treatment Regimens Effective in Latest Studies|
|The Need to Advocate for Fair HIV Drug Prices|
|'Stop Describing, Start Intervening': Can the CDC's New Viral Load Data Help Guide HIV Programs?|
|IL-1β Inhibitor Lowers Arterial Inflammation in Adults With Controlled HIV|
|Significant Interaction Between Once-Weekly Isoniazid/Rifapentine and Daily Dolutegravir: Study Stopped Due to Toxicity|